Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New HHS Chief Alex Azar Supports LDT Regulation, Cost-Saving Bundles

Executive Summary

Alex Azar was confirmed as the next secretary of Health and Human Services with strong industry support. Azar comes to the role with some homework to do on key FDA medtech policies, but has expressed support for risk-based regulation of lab-developed tests and cost-saving bundled-payment models.

You may also be interested in...



Sen. Schumer Calls On HHS Head Azar To Resign

Chuck Schumer, the top Democratic senator, is calling on HHS secretary Alex Azar to resign, accusing him of putting politics over public health.

HHS Chief Scores With Congress On DME Bid Program, Telehealth Pay, But Says LDTs Complex

At back-to-back congressional hearings on Feb. 14 and 15, US Health and Human Services Secretary Alex Azar seemed to satisfy lawmakers' questions on how he would use his budget to fix problems in the durable medical equipment bidding program and provide telehealth reimbursements under Medicare, but conceded that lab-developed test regulations are a complicated issue.

Gaps In Quality Measures Could Lead To Loss In Device Product Access, White Paper Says

The latest value-based payment models sponsored by the US Centers for Medicare and Medicaid Services and other institutions lack adequate quality measures to effectively assess the value of medical technologies. That's resulting in patients losing access to device products, says a Discern Health white paper sponsored by AdvaMed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel